Enhancing R&D in science-based industry: An optimal stopping model for drug discovery

International Journal of Project Management

Volumn 27, Issue 8, 2009, Pages 754-764

  Zhao, Guozhen ^a   Chen, Wen ^b  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Managing innovation; Optimal stopping problem; Pharmaceuticals; Project management procedure; R D project

Indexed keywords

CLINICAL TESTING; DECISION STRATEGY; DECISION-MAKING PRACTICES; DRUG DISCOVERY; DRUG RESEARCHERS; MANAGING INNOVATION; NUMERICAL EXAMPLE; OBJECTIVE FUNCTIONS; OPTIMAL STOPPING; OPTIMAL STOPPING PROBLEM; OPTIMAL STOPPING TIME; PHARMACEUTICALS;

DECISION MAKING; OPTIMIZATION; PROFITABILITY; PROJECT MANAGEMENT;

RESEARCH;

DECISION MAKING; DRUG; INNOVATION; MODELING; PHARMACEUTICAL INDUSTRY; PROJECT MANAGEMENT; RESEARCH AND DEVELOPMENT; SCIENCE AND TECHNOLOGY;

EID: 70349443509     PISSN: 02637863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijproman.2009.01.003     Document Type: Article

References (30)

1. Dougherty D. Reimagining the differentiation and integration of work for sustained product innovation. Organ Sci 12 5 (2001) 612-631
2. Elmquist M., and Segrestin B. Towards a new logic for front end management: from drug discovery to drug design in pharmaceutical R&D. Creativity Innov Manage 16 2 (2007) 106-120
3. Chen Y.-T., and Van den Ven A.H. Learning the innovation journey: order out of chaos. Organ Sci 7 (1996) 593-614
4. Gittins J. Quantitative methods in the planning of pharmaceutical research. Drug Info J 30 (1996) 479-487
5. Chi T., Liu J., and Chen H. Optimal stopping rule for a project with uncertain completion time and partial salvageability. IEEE Trans Eng Manage 44 1 (1997) 54-66
6. Talias M.A. Optimal decision indices for R&D project evaluation in the pharmaceutical industry: pearson index versus Gittins index. Eur J Oper Res 177 (2007) 1105-1112
7. McDonald R., and Siegel D. The value of waiting to invest. Quart J Econ 101 (1986) 707-728
8. Dixit A.K., and Pindyck R.S. Investment under uncertainty (1994), Princeton University Press, Princeton
9. Trigeorgis L. Real options: managerial flexibility and strategy in resource allocation (1996), MIT Press, Cambridge, Mass
10. Pisano G.P. Can science be a business? Lessons from biotech. Harvard Bus Rev 84 10 (2006) 114-125
11. Auyang SY. Chance and the prepared mind in drug discovery. Working paper, 2006. http://www.creatingtechnology.org/biomed/chance.pdf.
12. Garnier J.-P. Rebuilding the R&D engine in big pharma. Harvard Bus Rev 86 5 (2008) 68-76
13. Thomke S., Hippel E.V., and Franke R. Modes of experimentation: an innovation process and competitive-variable. Res Policy 27 (1998) 315-332
14. Thach C.T., and Fisher L.D. Self-designing two-stage trials to minimize expected costs. Biometrics 58 (2002) 432-438
15. Cressie N., and Biele J. A sample-size-optimal Bayesian procedure for sequential pharmaceutical trials. Biometrics 50 (1994) 700-711
16. Pindyck R.S. Investments of uncertain cost. J Financ Econ 34 (1993) 53-76
17. Roberts K., and Weitzman M.L. Funding criteria for research, development, and exploration projects. Econometrica 49 (1981) 1261-1287
18. Cohen M.A., Eliashberg J., and Ho T.H. New product development: performance and time-to-market tradeoff. Manage Sci 42 (1996) 173-186
19. Shepherd D.A., and Levesque M. A search strategy for assessing a business opportunity. IEEE Trans Eng Manage 49 1 (2002) 140-154
20. Savello D. Speeding new medicines to patients. Drug Discov Today 1 2 (1996) 45
21. Murray F. Innovation as co-evolution of scientific and technological networks: exploring tissue engineering. Res Policy 31 8-9 (2002) 1389-1403
22. Dunne D, Dougherty D. How and why science enhances exploratory product innovation: the case of bio-pharmaceutical drug discovery. Working paper. Binghamton University; 2008. ddunne@binghamton.edu.
23. Csete M.E., and Doyle J.C. Reverse engineering of biological complexity. Science 295 5560 (2002) 1664-1669
24. Bertels H, Chung K, Kraemer J, Zhao G, Dougherty D, Dunne D. What time is it? Coordinating pacing mechanisms in drug discovery. In: Academy of management best paper proceedings; August 2008.
25. Halliday R., Walker S., and Lumley C. R&D philosophy and management in the world's leading pharmaceutical companies. J Pharm Med 2 (1992) 139-154
26. Dyck WV. Predictive performance of front-loaded experimentation strategies in pharmaceutical discovery: a Bayesian perspective. DBA Thesis. School of Management, Cranfield University; 2004.
27. Ross S. Introduction to probability models. 9th ed. (2006), Academic Press
28. Zhao G, Chen W. An optimal stopping model for drug discovery. Working paper, 2008.
29. Tiggemann R.F., Dworaczyk D.A., and Sabel H. Project portfolio management: a powerful strategic weapon in pharmaceutical drug development. Drug Info J 32 (1998) 813-824
30. Eckhause J.M., Hughes D.R., and Gabriel S.A. Evaluating real options for mitigating technical risk in public sector R&D acquisitions. Int J Proj Manage 27 (2009) 365-377